Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers

NCT03981614 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT03981614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03981614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 2
Overall status
Completed
Start date
October 29, 2019
Completion date
July 2, 2024
Enrollment
102 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal carcinoma, stage iv colorectal cancer ajcc v8, stage iva colorectal cancer ajcc v8, stage ivb colorectal cancer ajcc v8, stage ivc colorectal cancer ajcc v8, unresectable carcinoma